Bluetooth enabled pacemaker for the first time in India

This advanced technology help in giving access to critical information anytime, anywhere. It allows remote monitoring which has proven to be resulting in higher survival rates.

Dr Viveka Kumar, Principal Diretor & Chief of Cath Labs (Pan Max), Institute of Cardiac Sciences, and team gave a new lease of life to 70 year old patient by implanting Bluetooth enabled pacemaker.

A 70 year old, a resident of Delhi, had been admitted to the hspital last month complaining of hypertension and fainting spells that had only intensified over the last few weeks. Her coronary angiography revealed single vessel disease due to which she had to undergo dual chamber permanent pacemaker implantation which was done in the same sitting.

Benefits to patients:

• The Bluetooth enabled pacemaker allows access to information anytime, anywhere as its BlueSync technology allows for tablet-based programming and app-based remote monitoring. Thus it reduces the hospital visites of patients significantly for follow-up check-ups.
• Patients can simply use their smartphones to transfer heart deivce data via the ap, even outside the home, replacing the bedside monitor and can even view select peacemaker data including model name and battery longevity. The battery of the device lasts for approximately 14years.
• The use of Bluetooth Low Energy is designed to minimize battery drain of this first ever FDA approved pacemaker and automatic notificatins keep patients informaed of the pulse transmission status.

• Bluetooth enabled pacemakers are quick in detecting and reducing cardiac arrhythmia thereby prviding patients with the highest standard of medical care.
• It also allows doctors the option to control max atrioventricular interval as notifications can be programmed and viewed only by the clinicians such as AT/AF burden notifications, lead impedance and rapid heartbeat episodes. Its PR Logic Algorithms help in accurate AF detection by reducing AT/AF false positives while its reactive ATP reduces progression of AF thereby reducing risk of persistent AF.